1. Within your health trust how many patients are currently [within the past 6 months available] being treated for head and neck cancer (Squamous cell carcinoma)?
2. Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
a. Locally advanced
b. Recurrent metastatic
3. Of the locally advanced/ recurrent or metastatic head and neck cancer patients how many are currently [within the past 6 months available]
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab (Erbitux) with/without chemotherapy
Cetuximab (Erbitux) with radiotherapy
Docetaxel (Taxotere) -only or in combination with 5-FU
Fluorouracil (5FU)
Radiotherapy only
Other
4. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials?
5. Within your health trust how many patients are currently [within the past 6 months available] being drug treated for metastatic colorectal cancer?
Of those patients please split by their drug treatment;
Cetuximab (Erbitux) with/without chemotherapy
Panitumumab (Vectibix) with/without chemotherapy
Nivolumab (Opdivo) with/without chemotherapy
Chemotherapy + other mAb
Chemotherapy alone
Other
6. Does your health trust participate in any ongoing clinical trials for the treatment of colorectal cancer patients, if so how many patients are currently taking part in clinical trials?
Download response Head and Neck Cancer (Squamous cell carcinoma). 260418